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A 48-year-old Hispanic male presented to the emergency 
department for medication refill for insulin-dependent diabetes 
mellitus. Upon presentation, the patient reported running out 
of insulin (Novolin) one month prior. The patient also noted 
increased swelling and pain in his right foot for approximately 
that same period of time. The patient denied any trauma to his 
right foot and reported pain with ambulation. He denied any 
other symptoms. On physical exam, the patient’s right foot 
appeared mildly swollen with tenderness to palpation over the 
medial aspect. There appeared to be an ulcer over the mid-
plantar surface, approximately 1cm by 1cm in size. There was 
no noted erythema, edema or purulent drainage. The patient 
had plain radiography of his right foot performed, including 
lateral, oblique and dorsoplantar weight-bearing views. 
The dorsoplantar weight-bearing view revealed a lisfranc 
dislocation with fragmentation, disorganization and swelling 
consistent with a charcot foot (Figure). There appeared to be 
lateral displacement between the 1st and 2nd metatarsals, with 
complete displacement of the 2nd – 5th metatarsals, consistent 
with a Type A Lisfranc injury. The patient was subsequently 
placed in a fracture boot, instructed to be non-weight bearing 
on the right lower extremity and provided with crutch 
teaching. He was referred to our diabetic foot clinic for further 
management and education. 
Jacques Lisfranc de Saint-Martin, a field surgeon in 
Napoleon’s army, first described the tarsometatarsal joint as 
a level for rapid forefoot amputation.1 The term “Lisfranc” 
would later be used to describe a variety of injuries at the 
tarsometatarsal joint, including ligamentous, fracture-
subluxation or fracture-dislocation. Lisfranc injuries are most 
commonly indirect and usually the result of axial loading or 
twisting on a plantar flexed foot.2
Charcot arthropathy, or neuropathic joint, is a progressive 
condition of bone and joint changes that occur secondary 
to sensory loss. It is characterized by joint dislocation, 
pathologic fracture and deformity.3 It was first described 
by William Musgrave in 1703 as an arthralgia caused by 
venereal disease.4 In 1868, Jean-Marie Charcot first described 
a hypertrophic process of destructive arthritis and it became 
known as “Charcot’s disease.”5 It almost exclusively occurs in 
the foot and ankle and is most commonly caused by diabetes 
Figure. Dorsoplantar radiograph revealing a Lisfranc dislocation 
with fragmentation, disorganization and swelling consistent with 
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mellitus.6 The neurotraumatic theory of Charcot arthropathy 
is an unperceived trauma or injury to an insensate foot that 
is worsened by microtrauma with continued ambulation. In 
diabetic patients, the incidence of Charcot arthropathy of the 
foot and ankle ranges from 0.15 -2.5%.7 The incidence of 
Lisfranc injuries is estimated at one per 55,000 and account 
for only 0.2% of all fractures. They occur more commonly in 
men and after the third decade of life.8
The treatment of Charcot arthropathy is primarily 
non-operative. In the acute phase, immobilization and 
non-weight bearing is key. Immobilization is typically 
accomplished by casting. Injuries with ulceration may require 
daily debridement and therefore benefit from removable 
immobilizers such as a walking boot or bivalve cast. Absolute 
non-weight bearing in the acute phase prevents continued joint 
destruction and should be instituted for 8-12 weeks.9 Casting 
may be necessary for 3-6 months and is discontinued based on 
clinical and radiographic evidence of quiescence. Operative 
management is generally reserved for severely displaced or 
unstable ankle, hindfoot and forefoot injuries. Recalcitrant 
ulceration may also require surgical intervention. Lifelong 
protection of the involved foot includes custom footwear, such 
as extra-depth shoes with rigid soles and professional foot care 
on a regular basis.
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